Although Akt is a determinant of cisplatin (cis-diaminedichloroplatinum (CDDP)) resistance in ovarian cancer cells, which is related in part to its inhibitory action on p53 activation, precisely how Akt confers CDDP resistance is unclear. In this study, we show that CDDP induced p53-dependent Fas-associated death domain-like interleukin-1b-converting enzyme (FLICE)-like inhibitory protein (FLIP) degradation in chemosensitive ovarian cancer cells but not their resistant counterparts. CDDP induced FLIP-p53-Itch interaction, colocalization and FLIP ubiquitination in chemosensitive but not chemoresistant ovarian cancer cells. Moreover, although activated Akt inhibited CDDP-induced FLIP degradation and apoptosis in sensitive cells, these responses were facilitated by dominant-negative Akt expression in chemoresistant cells. Inhibition of Akt function also facilitated p53-FLIP interaction and FLIP ubiquitination, which were attenuated by p53 silencing. These results suggest that Akt confers resistance, in part, by modulating CDDP-induced, p53-dependent FLIP ubiquitination. Understanding the precise etiology of chemoresistance may improve treatment for ovarian cancer.
Introduction
Although cisplatin (cis-diaminedichloroplatinum (CDDP))-centered chemotherapy is the first-line anticancer agent for human ovarian cancer, chemoresistance remains a major hurdle to successful treatment. Recent evidence indicates that the inability of the cells to undergo apoptosis is a key determinant of CDDP resistance (Cheng et al., 2002) . Dysregulation of pro-apoptotic (for example, Fas, caspases and p53; (Schneiderman et al., 1999; Fraser et al., 2008) ) and antiapoptotic (for example, Akt, X-linked IAP, Fas-associated death domain-like interleukin-1b-converting enzyme (FLICE)-like inhibitory protein (FLIP); Li et al., 2001; Fraser et al., 2003; Abedini et al., 2004; Dan et al., 2004) ) pathways has been shown in chemoresistant cells.
Fas-associated death domain-like interleukin-1b-converting enzyme-like inhibitory protein presents in two splice variants, long isoform of FLIP (FLIP L ) (55 kDa) and short isoform of FLIP (FLIP S ) (28 kDa). FLIP is a determinant of ovarian cancer chemoresistance, and CDDP decreases FLIP L and FLIP S contents (Abedini et al., 2004) . Moreover, CDDP induces FLIP ubiquitination and degradation in a p53-and Itch-dependent manner (Abedini et al., 2008) . The tumor-suppressor protein, p53, is a transcription factor regulating cell cycle, DNA repair and apoptosis, and is rapidly upregulated by DNA-damaging agents, including CDDP (Buttitta et al., 1997) .
Akt/protein kinase B promotes ovarian cells survival and malignant transformation (Shayesteh et al., 1999; Sun et al., 2001; Fraser et al., 2003) . It is a determinant of CDDP resistance, and activation of the PI-3K/Akt pathway increases FLIP mRNA and/or protein expression in human cancer cells (Panka et al., 2001; Suhara et al., 2001; Nam et al., 2002 Nam et al., , 2003 . However, whether and how Akt regulates CDDP-induced FLIP downregulation and apoptosis in chemoresistant cells is not clear.
In this study, we show that p53 facilitates FLIP-Itch interaction and FLIP ubiquitination and degradation in chemosensitive but not resistant cells. However, in chemoresistant cells, Akt inhibits FLIP-p53 interaction, FLIP ubiquitination and apoptosis, suggesting that Akt modulation may be an effective mean to overcome chemoresistance in human ovarian cancer. The data shown are representative results obtained from three independent experiments. *Po0.05, **Po0.01 and ***Po0.001 versus OV2008.
Results
CDDP-induced p53-FLIP interaction and FLIP ubiquitination are not observed in chemoresistant ovarian cancer cells Cis-diaminedichloroplatinum downregulates FLIP content and induces apoptosis in the chemosensitive but not resistant ovarian cancer cells (Abedini et al., 2004) . CDDP also induces FLIP-p53-Itch interaction and FLIP ubiquitination in chemosensitive cells (Abedini et al., 2008) . Here, we examined whether the inability of CDDP to downregulate FLIP in resistant cells is due to its failure to induce FLIP-p53-Itch interaction and FLIP ubiquitination. Chemosensitive cells (OV2008 and A2780s) and their resistant counterparts (C13* and A2780cp) were transfected with hemagglutinin (HAubiquitin) (2 mg; 24 h), infected with adenoviral V5-FLIP S , V5-FLIP L (multiple of infection (MOI) ¼ 25; 24 h) and treated with CDDP (0-10 mM) in the presence of the proteasome inhibitor epoxomicin (25 nM; to prevent the proteasomal degradation of ubiquinated FLIP) for 1.5 and 3 h. Protein-protein interaction and FLIP ubiquitination were determined by immunoprecipitation/western blot (IP-western). Although p53-FLIP-Itch interaction was not evident with IgG and in the absence of primary antibody (Figures 1a, 2a and 1c, 2c) , it was enhanced with CDDP treatment and associated with increased FLIP ubiquitination (Figures 1b, 2b and 1d, 2d) . FLIP-Itch and FLIP-p53 binding were significantly higher in chemosensitive cells than in the resistant counterparts in the absence of CDDP (control group; dimethyl sulfoxide) and were further enhanced in chemosensitive cells by CDDP (Figures 1a and c) , a response associated with FLIP ubiquitination (Figure 1b and d). Similar responses were observed in A2780s and A2780cp cells (Figures 2a-d) . These findings raise the possibility that the failure of CDDP to downregulate FLIP content in chemoresistant cells may be due to its inability to induce p53-FLIP-Itch interaction and FLIP ubiquitination.
CDDP induces FLIP-p53-Itch colocalization in chemosensitive but not resistant cells Cis-diaminedichloroplatinum induces colocalization of FLIP, p53 and Itch at the cell membrane in chemo- 
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Dysregulation of FLIP ubiquitination by Akt in chemoresistant ovarian cancer MR Abedini et al sensitive cells (Abedini et al., 2008) . To further investigate this phenomenon, we examined FLIP-p53-Itch colocalization by triple immunolabeling on chemosensitive cells (OV2008) and its resistant counterpart (C13*) treated with CDDP (0-2.5 mM, 2 h). In OV2008 cells treated with dimethyl sulfoxide (control; Figure  3a1 -4), FLIP-, Itch-and p53-immunoreactivities displayed clustered and diffuse staining throughout the cytoplasm and few triple colocalizations of FLIP, p53 and Itch clusters. OV2008 cells treated with CDDP exhibited a marked increase in the density of triple membrane colocalizations at the cell membrane only (Figure 3a5-8) . Fluorescence intensity profiles indicate clustered pattern (hot spots of fluorescence) along the plasma membrane in CDDP-treated OV2008 cells ( Figure 3b2 ) and diffuse fluorescence pattern on all other groups (constant fluorescence intensity; Figures 3b1, 3b3-b4). These observations were confirmed quantitatively by the findings that the proportions of FLIP, p53 and Itch clusters at the cell membrane increased (Po0.001), whereas those in other compartments decreased (Po0.001; Figure 3c ). The proportions of FLIP-p53 and FLIP-p53-Itch co-clusters were significantly increased (Po0.001) in cells treated with CDDP, also arguing for the recruitment of FLIP at the cell membrane in a FLIP-p53-Itch triple complex. C13* cells seemed to have diffused localization of Itch, p53 and FLIP in the cytosolic and membrane compartments. Two-way analysis of variance shows that although in the absence of CDDP the density of p53-FLIP and Itch clusters and co-clusters at the cell membrane in resistant cells were higher than their sensitive ones, CDDP decreased Itch reactivity at the membrane (Po0.05) and increased cytosolic FLIP content (Po0.05) (Figure 3c ). Moreover, no difference in the intracellular versus membranous distribution of FLIP, p53 and Itch clusters, nor an increase in the proportion of FLIP coaggregated with p53 or p53-itch co-clusters, was observed with CDDP ( Figure 3d ). Rather, C13* cells showed similar distribution pattern of FLIP, p53 and Itch individual or colocalized clusters in both intracellular and membranous compartment (Figure 3d ), indicating that chemoresistant cells show an intrinsic mechanism preventing FLIP to be recruited at the cell membrane.
Akt inhibits CDDP-induced FLIP downregulation and apoptosis in ovarian cancer cells Akt, a determinant of chemoresistance in ovarian cancer cells (Fraser et al., 2003) , upregulates FLIP expression (Panka et al., 2001; Suhara et al., 2001; Nam et al., 2003) . To investigate whether forced expression of an active Akt would inhibit CDDP-induced FLIP degradation and chemosensitivity, OV2008 cells infected with adenoviral HA-tagged activated Akt1 (AAkt1) or LacZ (MOI ¼ 0-10; 24 h) were incubated with CDDP (0, 2.5, 5 and 10 mM; 24 h). FLIP content and successful expression of the activated Akt1 were assessed. Although adenoviral active Akt1 had no effect on basal FLIP content and apoptosis, it significantly inhibited these responses to CDDP in a concentration-dependent manner ( Figure 4a ). Moreover, activated Akt2 (AAkt2; 2 mg; 24 h) also attenuated CDDP-induced FLIP L and FLIP S downregulation ( Figure 4b ) and apoptosis ( Figure 4b ) in OV2008 cells, suggesting that Akt activation suppresses CDDP-induced FLIP downregulation and apoptosis, regardless of its isoform.
To determine whether the above observation was cell line-specific, FLIP downregulation and apoptosis was assessed in chemosensitive A2780s (stably transfected with constitutively active Akt2 (A2780s-AAkt2) or the empty vector (A2780s-PMH6) treated with CDDP (0, 5 and 10 mM; 0-24 h). Although CDDP decreased FLIP content ( Figure 4c ) and induced apoptosis ( Figure 4c ) in A2780s-PMH6 cells, these responses in A2780s-AAkt2 cells were significantly lower. A2780s infected with adenoviral activated Akt1 (MOI ¼ 0-10; 24 h) and treated with CDDP (0-10 mM; 24 h; Figure 4d ) also showed significantly lower CDDP-induced FLIP downregulation and apoptosis.
Akt activity is a determinant of CDDP resistance (Fraser et al., 2003) . CDDP downregulates Akt and p-Akt content in sensitive but not resistant ovarian cancer cells (data not shown). To further investigate whether Akt modulate CDDP-induced proteasomal Figure 5c ). Taken together these findings suggest that Akt inhibits CDDP-induced FLIP downregulation by inhibiting its proteasomal degradation. In contrast to that observed in C13* cells (wt p53), expression of DN-Akt failed to sensitize A2780cp p53-mutant cells to CDDP-induced apoptosis (Figure 5b) .
To further examine the hypothesis that CDDPinduced apoptosis requires p53 function, HEY and OVCA433 cells (both wt-p53) (Hagopian et al., 1999) were infected with DN-Akt (MOI ¼ 0-80, 48 h), transfected with p53 or control small interfering RNA (siRNA) (100 nM; 24 h) and then cultured with CDDP (0-10 mM; 24 h). Expression of DN-Akt sensitized HEY and OVCA433 cells to CDDP-induced apoptosis (Po0.001, Figures 6a and b) , and p53 siRNA markedly attenuated this response (Po0.001). Moreover, OCC1 and OVCAR-3 cells (both p53 mutant) (Hagopian et al., 1999) were infected with adenoviral DN-Akt or LacZ (MOI ¼ 0-80; 48 h), and adenoviral p53 (MOI ¼ 0-10, 24 h), and treated for 24 h with CDDP (0-10 mM). Although DN-Akt expression failed to sensitize these cells to CDDP-induced apoptosis (Figures 6c and d) , coexpression of wt-p53 sensitized the cells to CDDP (Po0.001).
Akt suppresses p53-FLIP interaction and FLIP ubiquitination To examine whether Akt regulates p53-FLIP binding and FLIP ubiquitination, CDDP resistant cells (C13* and A2780cp) were infected with adenoviral DN-Akt (MOI ¼ 80; 48 h), transfected with HA-ubiquitin (2 mg; 24 h) and infected with either adenoviral V5-FLIP L or V5-FLIP S (MOI ¼ 25; 24 h). The cells were then transfected with control siRNA or p53 siRNA (100 nM; 24 h) and treated with CDDP (0-10 mM; 1.5-3 h) in the presence of epoxomicin (25 nM). FLIP-p53 interaction was not detected with nonspecific IgG, or in the absence of primary antibody or in cells only transfected with HA-ubiquitin (Figures 7a and c) . In the absence of DN-Akt, CDDP had no effect on p53-FLIP interaction and FLIP ubiquitination, but expression of DN-Akt increased p53-FLIP binding (Figure 7a and c) and FLIP ubiquitination (Figures 7b  and d) . These responses were attenuated by p53 silencing (Figures 7a-d) , suggesting the possibility that Akt prevents CDDP-induced FLIP downregulation by inhibiting p53-FLIP binding and FLIP ubiquitination in the chemoresistant cells.
Discussion
Using pairs of CDDP-sensitive parental ovarian cancer cell lines and their resistant variants, we have investigated the molecular mechanisms of chemoresistance. We have shown that (i) CDDP-induced FLIP ubiquitination and degradation is associated with chemosensitivity in ovarian cancer cells; (ii) p53 can interact with FLIP and Itch and induce FLIP ubiquitination and proteasomal degradation in sensitive but not in resistant cells; (iii) the CDDP-induced responses were regulated by Akt; and (iv) apoptotic response to CDDP was evident in wt-p53 but not mutant p53 chemoresistant cells following Akt downregulation. These findings suggest that Akt promotes chemoresistance, in part, by modulating CDDP-induced, p53-dependent FLIP ubiquitination.
We have shown that CDDP induces FLIP degradation (Abedini et al., 2004) and apoptosis (Li et al., 2000; Fraser et al., 2003; Abedini et al., 2004; Yang et al., 2006) in chemosensitive ovarian cancer cells but not their resistant counterparts. CDDP also induces FLIPp53-Itch interaction and colocalization at the cell membrane, and FLIP ubiquitination and proteasomal degradation (Abedini et al., 2008) . In this study, we have observed that the inability of CDDP to downregulate FLIP in wt-p53 chemoresistant cells is associated with and that CDDP-induced FLIP ubiquitination is dysregulated in chemoresistant cells, suggesting that attenuated FLIP ubiquitination may, in part, contribute to chemoresistance. Although other factors, such as X-linked IAP and p53, also regulate chemosensitivity in ovarian cancer cells Li et al., 2001; Fraser et al., 2003) , a difference in cellular CDDP retention does not seem to be an important contributing factor in chemoresistance in ovarian cancer cells (Mansouri et al., 2003) . Although FLIP ubiquitination has been shown in several cell lines Meinander et al., 2007; Zou et al., 2007) , the precise mechanism underlying FLIP ubiquitination was not determined. To our knowledge, this represents the first report on the aberrant regulation of FLIP ubiquitination in chemoresistant ovarian cancer cells. Itch-FLIP interaction is associated with colocalization at the cell membrane and FLIP ubiquitination and is enhanced by CDDP (Abedini et al., 2008) , suggesting that FLIP-Itch binding may be crucial for FLIP regulation, and that CDDP decreases FLIP content by enhancing FLIP-Itch interaction, FLIP ubiquitination and proteasomal degradation. Although FLIP L -Itch interaction (Chang et al., 2006) and FLIP ubiquitination has been reported in several cell subtypes Meinander et al., 2007; Zou et al., 2007; Abedini et al., 2008) , the importance of these phenomena in chemoresistance has not been determined. This study shows for the first time that Itch binds with both FLIP S and FLIP L to facilitate FLIP ubiquitination in chemosensitive but not their resistant counterparts. Our findings support the hypothesis that the inability of CDDP to induce FLIP-Itch interaction and subsequently FLIP ubiquitination contribute to CDDP resistance.
p53, a crucial apoptotic cell death mediator in ovarian cancer cells (Fraser et al., 2003) , and Itch facilitate FLIP ubiquitination and its proteasomal degradation in cancer cells of the colon (Fukazawa et al., 2001 ) and the ovary (Abedini et al., 2008) . In this study, we showed that CDDP induces FLIP-p53-Itch interaction and colocalization at the cell membrane in chemosensitive cells but not in their resistant counterparts. Interestingly, CDDP increased p53-FLIP but not p53-Itch colocalization at the cell membrane, suggesting that p53-FLIP interaction could occur before Itch recruitment and may be an obligatory step in p53-FLIP-Itch triple colocalization and FLIP ubiquitination.
Although C13* and A2780cp have higher basal p53 contents when compared with their chemosensitive counterparts, they were not affected by CDDP (Yang et al., 2006; Fraser et al., 2008) . Our current results show that the density of p53-FLIP-Itch co-clusters at the cell membrane was also higher in resistant cells in the absence of CDDP. As expected, CDDP induces p53 nucleus localization at 6-12 h, but interestingly not earlier (data not shown). It seems that p53-FLIP-Itch and FLIP ubiquitination precedes the nuclear accumulation of p53 (2 h versus 6-12 h). However, although CDDP failed to alter Itch-p53-FLIP interaction in resistant cells, the proportion of triple colocalization in sensitive cells was significantly increased in response to CDDP, at a level considerably higher than that observed in its resistant variant. This difference suggests that the lower CDDP-induced FLIP-p53 binding is a more important factor than altered total p53 content in conferring chemoresistance. This represents, to our knowledge, the first demonstration of a pathological condition under which p53-FLIP-Itch interaction is differentially regulated. Although p53 level is negatively associated with FLIP content (Fukazawa et al., 2001; Chandrasekaran et al., 2006) , our results show a higher proportion of p53-FLIP interaction in chemosensitive cells treated with CDDP, supporting our hypothesis that p53 serves as a docking protein in facilitating FLIP-Itch interaction and Itch-mediated FLIP ubiquitination (Abedini et al., 2008) . Furthermore, the lower proportion of p53, FLIP and Itch cross-interaction in chemoresistant cells when compared with chemosensitive cells could explain the abrogation of CDDPinduced FLIP degradation and apoptosis.
Akt/PI3K modulates the tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL)-and Fasmediated cell death by upregulating FLIP mRNA and/ or protein content in cancer cells, hepatocytes and endothelial cells (Panka et al., 2001; Nam et al., 2002 Nam et al., , 2003 Skurk et al., 2004; Alladina et al., 2005; Sta¨rck et al., 2005; Moriyama and Yonehara 2007; Moumen et al., 2007; Shim et al., 2007) . Here we show that Akt activation inhibited CDDP-induced FLIP downregulation and apoptosis in wt-p53 chemosensitive ovarian cancer cells (OV2008 and A2780s). Moreover, inhibition of Akt function facilitated CDDP-induced FLIP downregulation in the wt-p53 chemoresistant cells (C13*). DN-AKT reduced FLIP content to a greater extent at MOI ¼ 80 than MOI ¼ 40, although an increased cisplatin (10 mM) sensitivity was not evident, indicating that a threshold exists in FLIP downregulation in the induction of apoptosis in C13* cells. We further observed that downregulation of Akt function facilitates FLIP degradation through proteasome pathway. These findings confirm the role of Akt in CDDP resistance in ovarian cancer cells and support our contention that modulation of FLIP downregulation could be one mechanism by which Akt confers chemoresistance.
We observed that suppression of Akt function sensitizes wt-p53 (C13*, HEY and OVCA433) but not p53-mutant chemoresistant cells (A2780cp, OCC1 and OVCAR-3) to CDDP-induced apoptosis, suggesting that Akt-mediated chemoresistance may be mediated in part through suppression of p53 function. Although downregulation of Akt function facilitated FLIP ubiquitination and its degradation in this p53-mutant resistant cell line, CDDP-induced apoptosis was not evident, suggesting that FLIP downregulation in response to CDDP is necessary but not sufficient to induce apoptosis, which requires the presence of functional p53. This observation is consistent with our previous findings that DN-Akt expression is not able to facilitate CDDPinduced apoptosis in A2780cp cells unless reconstituted with wt-p53 (Fraser et al., 2003 (Fraser et al., , 2008 Yang et al., 2006) , a response which is significantly attenuated in the presence of pifithrin-a-hydrobromide, a specific inhibitor of p53 function (Fraser et al., 2003) . We have also showed that p53 silencing attenuates CDDP-induced mitochondrial Smac release and apoptosis in C13* cells stably transfected with DN-Akt2 (Yang et al., 2006) .
Inhibition of Akt function promotes CDDP-induced FLIP-p53 interaction, suggesting that Akt may regulate FLIP ubiquitination and its proteasomal degradation.
Thus, Akt may inhibit apoptosis, in part, by attenuating p53-mediated FLIP ubiquitination. Although p53 facilitates FLIP downregulation (Fukazawa et al., 2001) and p53 level and function could be correlated with FLIP downregulation in response to various cellular stimuli (Fukazawa et al., 2001; Chandrasekaran et al., 2006) , this report provides the first direct evidence for a role of p53 in FLIP degradation. Indeed, Akt has been shown to upregulate FLIP content (Panka et al., 2001; Suhara et al., 2001; Nam et al., 2002 Nam et al., , 2003 Skurk et al., 2004; Alladina et al., 2005; Sta¨rck et al., 2005; Moriyama and Yonehara 2007; Moumen et al., 2007; Shim et al., 2007) and/or to alter p53 content by activating MDM2 (Mayo and Donner 2001; Zhou et al., 2001; Milne et al., 2004) . Our results provide strong evidence that Akt may have a wide-ranging anti-apoptotic role, which includes interfering with the FLIP-p53 binding and FLIP ubiquitination. As p53-FLIP interaction is associated or correlated with p53-induced apoptosis (Abedini et al., 2008) , this strongly suggests that prevention of FLIP-p53 binding by Akt may be a mechanism by which Akt inhibits apoptosis and confers chemoresistance.
In summary, our studies clearly establish that FLIP ubiquitination is an important contributor to CDDPinduced FLIP degradation and apoptosis and show that chemoresistance is, in part, mediated through the ability of Akt to attenuate this p53-dependent process. Although FLIP ubiquitination does not require functional p53, CDDP-induced apoptosis is dependent on the p53 status. Furthermore, FLIP ubiquitination can be triggered by FLIP-p53 interaction in an Itchdependent manner, as downregulation of Itch by siRNA attenuates CDDP-induced FLIP ubiquitination in chemosensitive ovarian cancer cells (Abedini et al., 2008) . As FLIP-p53 interaction is attenuated in chemoresistant cells in response to CDDP and is restored by downregulation of Akt function, this phenomenon is likely to be a critical step in CDDP-induced apoptosis. On the basis of these findings, and to facilitate future investigations into the cellular mechanisms of CDDP resistant in ovarian cancer, a hypothetical model is proposed (Figure 8 ). Our results contribute to a better understanding of the mechanism(s) involved in CDDP resistance, which may improve treatment outcomes for human ovarian cancer. 
Materials and methods

Reagents
Cell culture and adenovirus infection
Chemosensitive (OV2008 and A2780s) and resistant (C13* and A2780cp, respectively), wt-p53 (HEY and OVCA433) and mutant (OCC1 and OVCAR-3) resistant ovarian cancer cells were cultured as previously reported (Hagopian et al., 1999; Fraser et al., 2003) . A2780s-AAkt2 and A2780s-PHM6 cells (generously provided by Dr Jin Cheng, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA), stably transfected with pcDNA3 vector (Invitrogen, Burlington, Ontario, Canada) containing constitutively active HA-tagged, myristoylated Akt2 or pcDNA3 alone, were cultured as previously reported (Kamarajan et al., 2003; Yang et al., 2006) . Cells were infected with appropriate adenoviral as indicated in the text. LacZ adenovirus was added to same total concentration of the virus in all treatment groups. Adenovirus infection efficiency (MOI ¼ 5; 24 h) was >90% (Fraser et al., 2003) . All the experiments with CDDP treatment were carried out in serum-free medium.
FLIP ubiquitination analysis
Ovarian cancer cells were transfected (Abedini et al., 2004) with HA-ubiquitin. After 24 h, the culture medium was replaced with fresh RPMI 1640 or Dulbecco's modified Eagle's medium F12 containing CDDP (0-10 mM) and epoxomicin, and the cells were cultured for additional 0-3 h. Cells were harvested for FLIP ubiquitination analyses as previously reported (Poukkula et al., 2005; Abedini et al., 2008) .
RNA interference
Ovarian cancer cells transfected for 24 h with p53 siRNA (100 nmol/l), Itch siRNA (100 nmol/l) or control siRNA (100 nmol/l) (Fraser et al., 2003; Abedini et al., 2008) were treated with CDDP and harvested for subsequent analysis.
Western blotting
Western blotting was carried out as previously described (Abedini et al., 2004) . Membranes were incubated overnight at 4 1C with anti-FLIP (NF6, 1:500), anti-glyceraldehyde phosphate dehydrogenase (1:2 000), anti-p53 (1:1 000), antiItch (1:500), anti-V5 (1:5000) or anti-HA (1:1000) primary antibodies, and subsequently in horseradish peroxidase-conjugated anti-rabbit or anti-mouse secondary antibody (1:1000-10 000) for 1 h at room temperature. Peroxidase activity was visualized with the enhanced chemiluminescent kit (Amersham Biosciences, Piscataway, NJ, USA). Results were scanned and analysed using Scion Image software (Scion, Inc., Frederick, MD, USA).
Assessment of apoptosis
Apoptosis was determined morphologically, using Hoechst 33258 nuclear stain (Abedini et al., 2008) . At least 200 cells were counted in each treatment group. The counter was 'blinded' to sample identity to avoid experimental bias.
Immunoprecipitation
The cultured cells were transfected or infected with cDNA and treated with CDDP. Immunoprecipitation was performed on whole cell lysates using anti-V5 and -p53 antibodies and immunoblotted for p53, Itch and V5, using antip53, anti-Itch and anti-V5 antibodies, respectively (Abedini et al., 2008) .
Immunocytochemistry and confocal microscopy
Immunofluorescence was performed on cultured OV2008 and C13* cells using anti-p53, anti-FLIP and anti-Itch (Fraser et al., 2008) for p53, FLIP and Itch, respectively, as previously reported (Abedini et al., 2008) . Quantifications were performed manually. A cluster was defined by a sharp increase in fluorescence (Muller et al., 2004) . Given the numerical aperture of the objective used (1.4), the size of one pixel was set to 0.057 mm (Pixel size ¼ ((0.46 Â wavelength emission)/NA))/3, according to Nyquist theorem). The minimum number of pixels forming a cluster was set to 10, corresponding to a minimum area of 0.0325 mm
2
. The criterion to define cluster colocalization was a superimposition of at least five pixels of each cluster. Data were from two different set of cells for each condition.
Statistical analyses
Results are expressed as mean±s.e.m. of at least three independent experiments. Data were analysed by two-way analysis of variance and Bonferroni post-hoc tests (PRISM software version 3.0 or 4.0, Graph Pad, San Diego, CA, USA). Statistical significance was inferred at Po0.05.
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